Zum Inhalt

International Journal of Clinical Oncology

Ausgabe 7/2020 Including Invited Review on Central statistical monitoring

Inhalt (29 Artikel)

Central statistical monitoring of investigator-led clinical trials in oncology

  • Invited Review Article

Marc Buyse, Laura Trotta, Everardo D. Saad, Junichi Sakamoto

Recent advances of the regulation roles of MicroRNA in glioblastoma

  • Review Article

Chengrui Yan, Xiangyi Kong, Shun Gong, Fengrui Liu, Yuanli Zhao

Practical guidance for the evaluation of disease progression and the decision to change treatment in patients with advanced gastric cancer receiving chemotherapy

  • Open Access
  • Review Article

Satoru Iwasa, Toshihiro Kudo, Daisuke Takahari, Hiroki Hara, Ken Kato, Taroh Satoh

Implementation of a molecular tumor board at a regional level to improve access to targeted therapy

  • Original Article

Héloïse Bourien, Alexandra Lespagnol, Boris Campillo-Gimenez, Ingrid Felten-Vinot, Jean-Philippe Metges, Romain Corre, Thierry Lesimple, Cédric le Marechal, Lise Boussemart, Solène-Florence Kammerer-Jacquet, Edouard le Gall, Florent Denoual, Marie de Tayrac, Marie-Dominique Galibert, Jean Mosser, Julien Edeline

Performance of three prognostic models in critically ill patients with cancer: a prospective study

  • Original Article

Frank D. Martos-Benítez, Hilev Larrondo-Muguercia, David León-Pérez, Juan C. Rivero-López, Versis Orama-Requejo, Jorge L. Martínez-Alfonso

A phase II study of adaptive two-step intensity-modulated radiation therapy (IMRT) with chemotherapy for loco-regionally advanced nasopharyngeal cancer (JCOG1015)

  • Original Article

Yasumasa Nishimura, Satoshi Ishikura, Taro Shibata, Takeshi Kodaira, Yoshinori Ito, Kazuhiko Tsuchiya, Yuji Murakami, Jun-ichi Saitoh, Tetsuo Akimoto, Kensei Nakata, Michio Yoshimura, Teruki Teshima, Takashi Toshiyasu, Yosuke Ota, Kazuki Ishikawa, Hidetoshi Shimizu, Toshiyuki Minemura, Kenichi Nakamura, Masahiro Hiraoka

Effect of tumor burden and growth rate on treatment outcomes of nivolumab in head and neck cancer

  • Original Article

C. Suzuki, N. Kiyota, Y. Imamura, J. Rikitake, S. Sai, T. Koyama, Y. Hyogo, Y. Nagatani, Y. Funakoshi, M. Toyoda, N. Otsuki, KI. Nibu, H. Minami

Urinalysis by combination of the dipstick test and urine protein–creatinine ratio (UPCR) assessment can prevent unnecessary lenvatinib interruption in patients with thyroid cancer

  • Original Article

Chie Masaki, Kiminori Sugino, Sakiko Kobayashi, Junko Akaishi, Kiyomi Y. Hames, Chisato Tomoda, Akifumi Suzuki, Kenichi Matsuzu, Takashi Uruno, Keiko Ohkuwa, Wataru Kitagawa, Mitsuji Nagahama, Koichi Ito

Phase II study of S-1-based sequential combination chemotherapy including oxaliplatin plus bevacizumab and irinotecan with or without cetuximab for metastatic colorectal cancer: the SOBIC trial

  • Original Article

Yoshihiko Nakamoto, Masafumi Noda, Ryuichi Mikami, Yukihiko Tokunaga, Tatsuo Okumoto, Takashi Kawamura, Hidetoshi Fujiwara, Sadayuki Doi, Naohiro Tomita

Phase II study of 5-fluorouracil–leucovorin plus bevacizumab for chemotherapy-naïve older or frail patients with metastatic colorectal cancer (OGSG 0802)

  • Original Article

Takashi Ohta, Takeshi Kato, Hisato Kawakami, Yasuhiro Miyake, Masahiro Goto, Shigeyoshi Iwamoto, Toshio Otsuji, Masato Nakamura, Naotoshi Sugimoto, Shu Okamura, Masahito Kotaka, Masaki Tsujie, Yukihiko Tokunaga, Hideyuki Mishima, Taishi Hata, Toshio Shimokawa, Yukinori Kurokawa, Taroh Satoh

Serum LOX-1 is a novel prognostic biomarker of colorectal cancer

  • Original Article

Chiyo Nakashima-Nakasuga, Shoichi Hazama, Nobuaki Suzuki, Yuki Nakagami, Ming Xu, Shin Yoshida, Shinobu Tomochika, Nobuyuki Fujiwara, Satoshi Matsukuma, Hiroto Matsui, Yukio Tokumitsu, Shinsuke Kanekiyo, Yoshitaro Shindo, Noriko Maeda, Ryouichi Tsunedomi, Michihisa Iida, Shigeru Takeda, Shigefumi Yoshino, Tomio Ueno, Yoshihiko Hamamoto, Hiroyuki Ogihara, Yoshinobu Hoshii, Hiroaki Nagano

Postoperative C-reactive protein/albumin ratio is a biomarker of risk of recurrence and need for adjuvant chemotherapy for stage III colorectal cancer

  • Original Article

Hiroya Matsuoka, Koji Ando, Qingjiang Hu, Yoko Zaitsu, Yasuo Tsuda, Yuichi Hisamatsu, Yuichiro Nakashima, Yasue Kimura, Eiji Oki, Masaki Mori

Expression and prognostic significance of epithelial tissue-specific transcription factor ESE3 in hepatocellular carcinoma

  • Original Article

Zhuozhen Lyu, Mingze Ma, Yantian Xu, Xinxing Wang, Yuhua Zhu, WanHua Ren, Tao Li

ACO2 and ANPEP as novel prognostic markers for gallbladder squamous cell/adenosquamous carcinomas and adenocarcinomas

  • Original Article

Ziru Liu, Zhulin Yang, Li Xiong, Daiqiang Li, Qiong Zou, Yuan Yuan

Construction and validation of a novel prognostic nomogram for patients with sarcomatoid renal cell carcinoma: a SEER-based study

  • Original Article

Guangdong Hou, Xi’an Li, Yu Zheng, Pengfei Liu, Fei Yan, Dongen Ju, Geng Zhang, Wanxiang Zheng, Ming Gao, Niuniu Hou, Jiarui Yuan, Fuli Wang, Jianlin Yuan

A new risk stratification model for intravesical recurrence, disease progression, and cancer-specific death in patients with non-muscle invasive bladder cancer: the J-NICE risk tables

  • Original Article

Makito Miyake, Hideyasu Matsuyama, Satoshi Teramukai, Fumie Kinoshita, Isao Yokota, Hiroaki Matsumoto, Keiji Shimada, Mitsuru Kinjyo, Tatsuro Shimokama, Koji Okumura, Masaya Yomenori, Hideki Enokida, Masayuki Nakagawa, Yasushi Nakai, Kiyohide Fujimoto

Atypical oncologic failure after laparoscopic and robot-assisted radical cystectomy at a single institution

  • Original Article

Masashi Kubota, Hidetoshi Kokubun, Ritsuki Yamaguchi, Shiori Murata, Noriyuki Makita, Issei Suzuki, Ryosuke Suzuki, Yohei Abe, Yoichiro Tohi, Naofumi Tsutsumi, Yoshio Sugino, Koji Inoue, Mutsushi Kawakita

External validation of the "optimal PSA follow-up schedule after radical prostatectomy” in a new cohort

  • Original Article

Yoshinori Yanai, Kazuhiro Matsumoto, Takeo Kosaka, Toshikazu Takeda, Nobuyuki Tanaka, Shinya Morita, Ryuichi Mizuno, Toshiaki Shinojima, Hiroshi Asanuma, Mototsugu Oya

Small-volume lymph node involvement and biochemical recurrence after robot-assisted radical prostatectomy with extended lymph node dissection in prostate cancer

  • Original Article

Shuichi Morizane, Masashi Honda, Ryutaro Shimizu, Shogo Teraoka, Ryoma Nishikawa, Panagiota Tsounapi, Yusuke Kimura, Hideto Iwamoto, Katsuya Hikita, Atsushi Takenaka

Surgical outcomes of early-stage primary vaginal nonsquamous cell carcinoma

  • Original Article

Hidetaka Nomura, Yuji Tanaka, Makiko Omi, Sachiho Netsu, Yoichi Aoki, Terumi Tanigawa, Tomoko Kurita, Maki Matoda, Sanshiro Okamoto, Kohei Omatsu, Hiroyuki Kanao, Nobuhiro Takeshima

Clinical significance of thermal detection of soft-tissue tumors

  • Original Article

Akiyoshi Shimatani, Manabu Hoshi, Naoto Oebisu, Tadashi Iwai, Naoki Takada, Hiroaki Nakamura

Management and outcome of pediatric Wilms tumor with malignant inferior Vena cava thrombus: largest cohort of single-center experience

  • Original Article

Moatasem Elayadi, Mahmoud Hammad, Kareem Sallam, Gehad Ahmed, Soha Ahmed, Ahmed Ibrahim, Amal Refaat, Naglaa Elkinaai, Alaa Younes, Norbert Graf, Wael Zekri

Utility of whole brain radiation therapy for leptomeningeal carcinomatosis

  • Original Article

Yasuhiro Hirano, Kei Konishi, Yasuo Ejima

Neu im Fachgebiet Onkologie

Läuft PAXG beim Pankreaskrebs mFOLFIRINOX den Rang ab?

In der perioperativen Chemotherapie des pankreatischen duktalen Adenokarzinoms markiert das mFOLFIRINOX-Schema bis dato eine Art Standard der Behandlung. Ein italienisches Onkologie-Forschungsteam wartet nun mit einem alternativen Vorschlag auf.

Glioblastom: Auf diese PPI sollten Sie verzichten

Eine Metaanalyse aus fünf Studien zeigt: Die Einnahme von Protonenpumpenhemmern (PPI) bei neu diagnostiziertem Glioblastom ist mit einem schlechteren Überleben assoziiert – allerdings nicht bei allen PPI.

Perioperative Ernährungstherapie oft nicht leitliniengerecht

Beim Ernährungsmanagement vor und nach einer Krebs-Op. im Gastrointestinaltrakt klafft offenbar eine große Lücke zwischen Leitlinienempfehlungen und klinischer Praxis. Darauf deuten die Ergebnisse einer Umfrage in 263 deutschen Zentren hin.

DLBCL: Therapiedeeskalation auch bei Älteren möglich?

Ergebnisse der französischen Nichtunterlegenheitsstudie LNH2009-1B sprechen dafür, dass eine am metabolischen Ansprechen ausgerichtete Abrüstung der Chemoimmuntherapie bei älteren Personen mit neu diagnostiziertem DLBCL der Standardtherapie nicht unterlegen ist.

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Bildnachweise
Infusion/© Trsakaoe / stock.adobe.com, Mann hält Tablette und Wasserglas/© Syda Productions / stock.adobe.com (Symbolbild mit Fotomodell), Person isst eine Krankenhaus-Mahlzeit/© gballgiggs / Stock.adobe.com (Symbolbild mit Fotomodell), Konsolidierende Radiotherapie bei DLBCL mit in der Positronenemissionstomographie (PET) positivem Restbefund./© Oertel, M., Eich, H.T. / all rights reserved Springer Medizin Verlag GmbH